Andrew Ostrowski, MD
Urology · Marietta, GANPI 1831505361
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 62.5% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2023 at $8,303 and has fallen 78.2% since, to $1,810 in 2025.
Across 229 payments — averaging $79.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$11K
- Teleflex LLC$2K
- Procept Biorobotics Corporation$797
- Endo Pharmaceuticals Inc.$745
- Sumitomo Pharma America, Inc.$532
- Astellas Pharma US Inc$332
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$9,85054%
- Travel & lodging$6023%
- Food & beverage$7,49341%
- Education$1691%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 58 | $11,319 |
| Teleflex LLC | 24 | $2,203 |
| Procept Biorobotics Corporation | 8 | $797 |
| Endo Pharmaceuticals Inc. | 30 | $745 |
| Sumitomo Pharma America, Inc. | 26 | $532 |
| Astellas Pharma US Inc | 8 | $332 |
| Endo USA, Inc. | 14 | $324 |
| Boston Scientific | 8 | $234 |
| Myriad Genetic Laboratories, Inc. | 7 | $231 |
| Neotract Inc. | 1 | $142 |
| Conmed Corporation | 1 | $123 |
| KARL Storz Endoscopy-america | 1 | $122 |
| Metuchen Pharmaceuticals | 1 | $121 |
| Urovant Sciences Inc | 6 | $120 |
| Convatec Inc. | 4 | $110 |
| Novo Nordisk | 2 | $53 |
| Coloplast | 3 | $49 |
| Axonics, Inc. | 1 | $46 |
| Olympus America Inc. | 3 | $46 |
| Tolmar, Inc. | 2 | $43 |
| AbbVie | 2 | $42 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $39 |
| Antares Pharma, Inc. | 2 | $39 |
| Verity Pharmaceuticals Inc. | 2 | $38 |
| Zyla Life Sciences, Inc. | 2 | $37 |
| Dendreon Pharmaceuticals LLC | 1 | $30 |
| Merck | 1 | $26 |
| Laborie Medical Technologies Corp. | 1 | $26 |
| Myovant Sciences Inc. | 1 | $26 |
| Calyxo, Inc. | 1 | $21 |
| Bayer | 1 | $21 |
| Blue Earth Diagnostics | 1 | $20 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| Accord Healthcare, Inc. | 1 | $19 |
| Rochester Medical Corporation | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$10,188
- UroLift$886
- UroLift System$724
- AQUABEAM SYSTEM$340
- AquaBeam Robotic System$325
- XIAFLEX$236
- AIRSEAL$123
- Stendra$121
- Prolaris$110
- LYNX$109
How this compares
$18,114 in reported general payments places this provider in the 85th percentile of 369 urology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 221 | $183,394 |
| MyrbetriqMirabegron | 51 | $47,699 |
| OrgovyxRelugolix | 12 | $32,823 |
| Methenamine Hippurate | 39 | $6,848 |
| Tamsulosin Hcl | 484 | $4,962 |
| Trospium Chloride ErTrospium Chloride | 11 | $3,628 |
| Silodosin | 39 | $2,724 |
| Estradiol | 46 | $2,420 |
| Potassium Citrate ErPotassium Citrate | 20 | $2,337 |
| Testosterone Cypionate | 55 | $1,802 |
| Solifenacin Succinate | 26 | $1,386 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 57 | $859 |
| Finasteride | 72 | $827 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 60 | $786 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 171 | $596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $532 | $216,217233 claims |
| Astellas Pharma US IncMyrbetriq | $332 | $47,69951 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 369 urology providers in Georgia.
Other urology in Marietta
- Froylan GonzalesMarietta$35K
- Jason LomboyMarietta$23K
- Nikolas SymbasMarietta$23K
- Vahan KassabianRoswell$1.6M
- Lewis KritemanRoswell$864K
- Daniel CanterDecatur$329K
- Tariq HakkyAtlanta$140K
- Sherita KingAugusta$108K
- Brittani Barrett-HarlowFayetteville$100K
- James BennettAtlanta$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.